Loading…
← CockpitCompetitor Analysis › 2696.HK Shanghai Henlius Biotech, Inc. Class HOpen in the cockpit ↗

Shanghai Henlius Biotech, Inc. Class H2696.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biopharma making biosimilar and innovative monoclonal antibodies for oncology and autoimmune disease.

≈ A Chinese Amgen-biosimilars-style oncology antibody makerMomentum laggard 18
Mkt cap
$3.05B
US dollars, full cap
Free float
17%
of shares outstanding
$/day
$4.38M
20-day average traded
Fwd P/E
21.3×
forward earnings
ROIC−WACC
+1.7 pp
WACC 7.7%
Hurdle
-47 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · HKDHK$43.46
1D-1.0%
1W-12.9%
1M-16.9%
3M-33.7%
6M-38.5%
YTD-23.8%
1Y-29.9%
ATR %7.0%
52w lowhigh50.1% off high

What Shanghai Henlius Biotech does

Chinese biopharma making biosimilar and innovative monoclonal antibodies for oncology and autoimmune disease.

Earns from selling its own antibodies in China, from licensing overseas rights to partners that pay upfront and milestone fees and then buy supply, and from biosimilars, lower-cost versions of established cancer drugs. Fosun Pharma is the controlling shareholder.

In one line: A Chinese Amgen-biosimilars-style oncology antibody maker.

Products and services

  • Trastuzumab biosimilar (HER2)
  • Rituximab biosimilar
  • Bevacizumab biosimilar
  • Innovative PD-1/oncology pipeline

Customers

  • Hospitals/oncologists in China and emerging market

Where it sits in the supply chain

  • Biotechnology
  • Biosimilar monoclonal antibodies
  • Oncology/immunology biologics

What could go right

  • Biosimilar exports to emerging markets
  • New approvals

What could go wrong

  • Biosimilar pricing pressure
  • Parent (Fosun) related-party dependence

Moat: narrow (regulatory licence, scale, process know-how). Approved biosimilar manufacturing and regulatory track record across multiple markets.

Headquarters: Shanghai, China · Founded: 2010 · Employees: 3,762

Named competitors

Shanghai Henlius Biotech at a glance

Size Shanghai Henlius Biotech (2696.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.05B, the 329th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$43.46 on 18 Nov 2026.

Performance Over six months the shares fell 38.5%, against -1.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 32.6% over the last twelve months (peer median +14.8%); the operating margin is 12.0% (peer median 14.4%).

Valuation It trades at 21.3× forward earnings against a peer median of 21.5× (9th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -47 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.7 points above its cost of capital (7.7% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 1012696.HK 61
Six months, rebased to 100: Shanghai Henlius Biotech against the median of its 20 peers (local-currency closes).

Shanghai Henlius Biotech financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$8.30BHK$7.23BHK$6.21BHK$5.96BHK$3.74B
Revenue growth—+16%+4%+59%—
Gross profitHK$6.13BHK$5.36BHK$4.48BHK$4.26BHK$2.65B
EBITDAHK$1.47BHK$1.35BHK$1.35BHK$1.09B-HK$176M
Net incomeHK$969MHK$897MHK$890MHK$603M-HK$809M
Free cash flowHK$855MHK$957MHK$1.02BHK$491MHK$334M
Capital expenditureHK$1.62BHK$1.30BHK$908MHK$1.12BHK$1.59B
Total debtn/aHK$4.01BHK$3.88BHK$4.51BHK$4.14B

Quarterly statements and history in the cockpit →

Shanghai Henlius Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%ACADVCEL002773LEGN6882660867NEULANDLAB600535600380VKTX000739PPLPHARMA2096VRDNAMLX3005580022623001996881802696.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Henlius Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×ACADVCEL002773LEGN6882660867NEULANDLAB600535600511000739PPLPHARMA20963005583001992696.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Henlius Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%ACADVCEL00277368826608676005356005116003803005583001992696.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Henlius Biotech is the large dot.

Shanghai Henlius Biotech competitors and peer comparison

Head to head with its named competitors (2696.HK vs 1801.HK vs 1877.HK vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Henlius Biotech 2696.HK$3.05B-39%+33%12%21.3×14.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%n/an/a
Amgen AMGN$240B+34%+9%36%18.3×1.6%
Celltrion 068270.KS$34.9B+12%+40%32%33.9×10.6%

How Shanghai Henlius Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Henlius Biotech against its 20 peers (data as of 18 Nov 2026)
Measure2696.HKPeer medianRank in peer set
1-month return-16.9%-0.1%3rd lowest of 21
6-month return-38.5%-1.3%2nd lowest of 21
Distance from 52-week high-50.1%-25.0%3rd lowest of 21
Revenue growth (TTM)+32.6%+14.8%6th highest of 20
Operating margin12.0%14.4%10th highest of 19
Forward P/E21.3×21.5×9th cheapest of 17
Growth the price implies (Req g, 7 yrs)14.1%1.1%5th most demanding of 14
Growth delivered (Del g)+61.4%+7.0%2nd highest of 14
Hurdle (Req g minus delivered)-47.3 pp-10.1 pp2nd least demanding of 14
ROIC minus cost of capital+1.7 pp+4.3 pp8th lowest of 17
EV / EBITDA18.7×27.6×4th cheapest of 8
Net debt / EBITDA2.5×-1.9×2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a

Questions

Who are Shanghai Henlius Biotech's main competitors?
Named competitors: Innovent Biologics (1801.HK), Junshi Biosciences (1877.HK), Amgen (AMGN), Celltrion (068270.KS). The cockpit's measured peer set (industry) also includes ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), Chengdu Kanghong Pharmaceutical (002773.SZ), Legend Biotech Corp. Sponsored ADR (LEGN), Suzhou Zelgen Biopharmaceuticals (688266.SS), China Medical System (0867.HK).
Is Shanghai Henlius Biotech expensive compared with its peers?
On forward p/e it trades at 21.3× against a peer median of 21.5×, 9th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -47 pp: the price already allows for a slowdown.
How has Shanghai Henlius Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -38.5% against -1.3% for the median peer; over one year -29.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.